Assessment of Regional Response With PET-FDG in Advanced Head and Neck Squamous Cell Carcinoma (pet)
Primary Purpose
Head and Neck Squamous Cell Carcinoma
Status
Unknown status
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
pet scan
Sponsored by
About this trial
This is an interventional diagnostic trial for Head and Neck Squamous Cell Carcinoma focused on measuring HNSCC biopsy-proven, T1-T4 oral cavity oropharynx hypopharynx larynx, N+ scheduled for an organ preservation treatment protocol based on concomitant, chemoradiation
Eligibility Criteria
Inclusion Criteria:
- Biopsy-proven HNSCC
- Clinical stage: unpreviously treated T1-T4 oral cavity, oropharynx, hypopharynx, larynx
- Only patients suitable for at least a neck dissection after chemoradiotherapy will be included. Consequently, inclusion criteria are thus : T1-T4 , N1 N2a, N2b N2c N3 M0.
- Patient scheduled for an organ preservation treatment protocol based on concomitant chemoradiation (induction chemotherapy is allowed if this approach is followed by concomitant chemoradiation)
Sites / Locations
- Cliniques Universitaires Saint-LucRecruiting
Outcomes
Primary Outcome Measures
Efficacy of PET scan in evaluation of patient with HNSCC regionally advanced
Secondary Outcome Measures
Full Information
NCT ID
NCT00634777
First Posted
March 6, 2008
Last Updated
July 19, 2011
Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Collaborators
Jules Bordet Institute, University of Liege, Rennes University Hospital, Nantes University Hospital, Gustave Roussy, Cancer Campus, Grand Paris, University Hospital, Paris, Poitiers University Hospital, University Hospital, Toulouse, University Hospital, Rouen, University Hospital, Montpellier, Central Hospital, Nancy, France, Centre Oscar Lambret
1. Study Identification
Unique Protocol Identification Number
NCT00634777
Brief Title
Assessment of Regional Response With PET-FDG in Advanced Head and Neck Squamous Cell Carcinoma
Acronym
pet
Official Title
Assessment of Regional Response With PET-FDG in Advanced Head and Neck Squamous Cell Carcinoma
Study Type
Interventional
2. Study Status
Record Verification Date
July 2011
Overall Recruitment Status
Unknown status
Study Start Date
January 2007 (undefined)
Primary Completion Date
January 2012 (Anticipated)
Study Completion Date
January 2012 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Collaborators
Jules Bordet Institute, University of Liege, Rennes University Hospital, Nantes University Hospital, Gustave Roussy, Cancer Campus, Grand Paris, University Hospital, Paris, Poitiers University Hospital, University Hospital, Toulouse, University Hospital, Rouen, University Hospital, Montpellier, Central Hospital, Nancy, France, Centre Oscar Lambret
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Patients with advanced head and neck squamous cell carcinoma (HNSCC) may benefit from organ-preservation treatment based on combination of chemotherapy and radiotherapy without compromising disease-free and overall survival. In patients with initially advanced regional disease, there is controversy about the place of routine planned lymph node neck dissection after chemoradiotherapy, especially in responding patients without clinically invaded residual lymph nodes. There is uncertainty about the lymph nodes status after chemoradiation because the structural imaging modalities (CT, MRI) lack sensitivity and specificity : small positive lymph nodes are not detected, and residual large lymph nodes can be sterilized ( " ghosts nodes " with no sign of viable tumor cells at histopathology). Despite the absence of evidence based on prospective study, in numerous institutions currently, head and neck surgeons are quite reluctant to operate on for neck dissection patients with a complete clinical and radiological response following chemoradiation.
Metabolic imaging of tumors using PET and the glucose analog FDG has proven effective in head and neck SCC, especially after treatment to differentiate disease progression from radiation-induced inflammation.1 Several studies have shown that the metabolic response could predict the presence or absence of residual tumor cells in the primary tumor as well as the probability of relapse .2-4 Conflicting results have been reported on the use of PET to predict the pathological nodal status after chemoradiation, with negative predictive values ranging from 14 % to 100 %.5,6 Discrepancies observed might be due to the fact that PET was performed at variable time points after the end of radiotherapy. Ideally, PET should be performed as late as possible so that tumor regrowth can begin and become detectable, increasing the sensitivity of the procedure.
Detailed Description
- The primary objective is to assess the negative predictive value (NPV) of PET as a single examination in correctly predicting the absence of remaining invaded lymph nodes after chemoradiotherapy for advanced HNSCC.
Secondary objectives include :
The evaluation of the suitability of a wait and see approach without neck dissection in patients considered as complete responders ( based on clinical evaluation and imaging assessment including PET : all these diagnosis tools should be negative to consider a patient as a complete responder); this suitability will be estimated using the negative predictive value of the overall assessment of a complete response including PET-FDG but also the clinical evaluation and imaging.
The evaluation of the ability of PET-FDG to correctly predict remaining pathologically invaded lymph nodes (PPV) after chemoradiotherapy for advanced HNSCC in patients with a postchemoradiation positive PET a (and who will therefore be considered with less than a complete regional or locoregional response and who will undergo at least neck dissection.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Head and Neck Squamous Cell Carcinoma
Keywords
HNSCC biopsy-proven, T1-T4 oral cavity oropharynx hypopharynx larynx, N+ scheduled for an organ preservation treatment protocol based on concomitant, chemoradiation
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
239 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Other
Intervention Name(s)
pet scan
Intervention Description
pet scan
Primary Outcome Measure Information:
Title
Efficacy of PET scan in evaluation of patient with HNSCC regionally advanced
Time Frame
12 weeks after chemoradiation
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Biopsy-proven HNSCC
Clinical stage: unpreviously treated T1-T4 oral cavity, oropharynx, hypopharynx, larynx
Only patients suitable for at least a neck dissection after chemoradiotherapy will be included. Consequently, inclusion criteria are thus : T1-T4 , N1 N2a, N2b N2c N3 M0.
Patient scheduled for an organ preservation treatment protocol based on concomitant chemoradiation (induction chemotherapy is allowed if this approach is followed by concomitant chemoradiation)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marc Hamoir, MD
Phone
+3227641974
Email
marc.hamoir@uclouvain.be
First Name & Middle Initial & Last Name or Official Title & Degree
Sandra Schmitz, MD
Phone
+32427641976
Email
schmitz_sany@hotmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marc Hamoir, MD
Organizational Affiliation
Cliniques Universitaires Saint-Luc, Brussels
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Guy Andry, MD
Organizational Affiliation
Institut Jules Bordet, Brussels
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cliniques Universitaires Saint-Luc
City
Brussels
ZIP/Postal Code
1200
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Liza Nguyen Gia, MSc
Phone
+3227641274
Email
liza.nguyen-gia@uclouvain.be
First Name & Middle Initial & Last Name & Degree
Sandra Schmitz, MD
Phone
+3227641976
Email
schmitz_sany@hotmail.com
First Name & Middle Initial & Last Name & Degree
Marc Hamoir, MD
First Name & Middle Initial & Last Name & Degree
Max Lonneux, MD
12. IPD Sharing Statement
Learn more about this trial
Assessment of Regional Response With PET-FDG in Advanced Head and Neck Squamous Cell Carcinoma
We'll reach out to this number within 24 hrs